{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"submitter":["Kevin Schmidt"],"organism":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-16034"],"description":["This study aimed to explore the therapeutic potential of the cysteine protease inhibitor aloxistatin (E64d) as a candidate to combat cardaic fibrotic progression. Human cardiac fibroblasts (HCFs) derived from diseased myocardium including ischemic and dilated cardiomyopathies (ICM, DCM) were treated for 48 h with 100 µM aloxistatin or DMSO control and pro-fibrotic stimulated with 5 ng/mL TGFβ1 or respective vehicle (veh) control (4 mM HCl containing 0.1% bovine serum albumin). HCF were harvested with QiAzol Lysis reagent (Qiagen) and RNA was isolated based on phenol-chloroform-extraction procedure."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Nucleic Acid Extraction - RNA was isolated based on phenol-chloroform-extraction procedure.","Library Construction - polyA enrichment library preparation was performed by Novogene","Sample Collection - HCF were harvested with QiAzol Lysis reagent (Qiagen)","Sequencing - Illumina (NovaSeq X Plus) platform was used for paired end 150 bp sequencing (30 M reads per sample). Sequencing was done by Novogene."],"figure_sub":["Organization","MINSEQE Score","Assays and Data","Processed Data","MAGE-TAB Files"],"data_protocol":["Data Transformation - DESeq2 pipeline (for R) was used for count normalization and DEG calculation with default parameters","Sequence Alignment - mapping to GRCh38 with STAR aligner using default parameters"],"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"instrument_platform":["Illumina NovaSeq X"],"study_type":["RNA-seq of coding RNA"],"species":["Homo sapiens"],"pubmed_authors":["Maria Jordan","Kevin Schmidt","jan Fiedler"],"additional_accession":[]},"is_claimable":false,"name":"mRNA-seq of human cardiac fibrobasts (HCF) profibrotic stimulated with TGFb and treated with aloxistatin (E64d)","description":"This study aimed to explore the therapeutic potential of the cysteine protease inhibitor aloxistatin (E64d) as a candidate to combat cardaic fibrotic progression. Human cardiac fibroblasts (HCFs) derived from diseased myocardium including ischemic and dilated cardiomyopathies (ICM, DCM) were treated for 48 h with 100 µM aloxistatin or DMSO control and pro-fibrotic stimulated with 5 ng/mL TGFβ1 or respective vehicle (veh) control (4 mM HCl containing 0.1% bovine serum albumin). HCF were harvested with QiAzol Lysis reagent (Qiagen) and RNA was isolated based on phenol-chloroform-extraction procedure.","dates":{"release":"2026-07-06T00:00:00Z","modification":"2026-07-06T15:05:10.4Z","creation":"2025-11-13T14:50:12.194Z"},"accession":"E-MTAB-16034","cross_references":{"ENA":["ERP183922"],"EFO":["EFO_0002944","EFO_0004170","EFO_0004917","EFO_0005518","EFO_0003816","EFO_0003738","EFO_0004184"]}}